「risk」の検索結果

Use when planning, reviewing, or troubleshooting Salesforce metadata releases and admin deployment processes. Triggers: 'change set', 'deployment plan', 'rollback', 'DevOps Center', 'SFDX deploy', 'release checklist', 'production deployment', 'validation only deploy', 'quick deploy', 'test level', 'rollbackOnError', 'destructive changes', 'package.xml for an admin release', 'deployment status'. NOT for change set upload mechanics — use devops/change-set-deployment. NOT for scoring release risk up front — use admin/deployment-risk-assessment.

日本語の概要は準備中です。原文の説明を表示しています。

This is the MistEye security gate skill. It is triggered by pre-installation risk checks (including Skill/MCP dependency manifests), pre-access security checks for domains or URLs, IoC malicious detection, and supply-chain risk blocking, especially for common requests such as "take a look at this address/website." It must use `https://app-api.misteye.io/functions/v1/detect`; in dependency and external-link scenarios it has the highest priority. If the API returns `status="malicious"` or any `matches`, the action must be blocked and explicitly reported as "blocked". Only after the first installation is complete should the user be reminded that daily patrols can be enabled with OpenClaw or Hermes (default once per day).

日本語の概要は準備中です。原文の説明を表示しています。

Automate 21risk tasks via Rube MCP (Composio). Always search tools first for current schemas.

日本語の概要は準備中です。原文の説明を表示しています。

[user] Business Legal Counsel / CLO level contract drafting, review, and legal risk assessment. Handles domestic Chinese contracts (中文), cross-border contracts, and offshore international contracts in Chinese and English. Jurisdictions: PRC law (Civil Code, Company Law, Anti-Unfair Competition Law), US law (UCC, common law), Hong Kong law (common law, HK ordinances). Combines relevant laws, regulations, and litigation case precedents in contract analysis. Generates Word (.docx) files with track changes and persuasive margin comments for contract review markup. Use when user mentions contracts, legal review, contract drafting, legal risk assessment, NDA, agreement, 合同, 法律, 审核, 起草, 合同审查, 法务, legal negotiation, due diligence, 尽职调查, 风险评估, 条款谈判, 反不正当竞争, or any contract-related task.

日本語の概要は準備中です。原文の説明を表示しています。

Drafts privilege-protective, board-ready executive summary memoranda of internal antitrust investigation findings for US federal law. Covers monopolization, vertical restraints, acquisitions, FTC Act Section 5, tech-platform conduct, risk assessment, and remediation. Use when drafting antitrust investigation summaries, board memos on competition risk, or internal compliance investigation reports.

日本語の概要は準備中です。原文の説明を表示しています。

AI合同风控官 - 智能合同审查与法律风险检测专家级工具。支持多国法律体系（中国/美国/英国/新加坡/德国/日本/澳大利亚/加拿大/欧盟），可批量处理合同文档。 当用户需要：合同审查、合同风险检测、合同条款分析、法律文书审核、采购合同审核、销售合同审查、 劳动合同检查、合作协议评审、违约风险提示、合同比对、法务辅助、合同审计、批量合同审核、 外贸合同审查、国际合同合规、NDA保密协议审核、服务合同审查、租赁合同检查、股权转让协议审核、 借款担保合同审查 时触发此技能。

日本語の概要は準備中です。原文の説明を表示しています。

Coordinates staged or parallel jobs across live-verified coding-agent runtimes (Claude Code, Codex, Cursor, and other installed CLIs) and in-session toolkit subagents. Routes each job by capability and risk tier, isolates parallel writers in git worktrees, captures redacted output, resumes interrupted runs, and blocks completion until an independent arbiter verifies the results. Use when work should be split across multiple runtimes or subagents, run as staged or parallel jobs, and reviewed before handoff. NOT for a single-agent task or the in-session 7-phase flow (use mk:cook / mk:workflow-orchestrator).

日本語の概要は準備中です。原文の説明を表示しています。

Assess the reliability of companies and individuals through Openapi Risk - credit scores, CRIF reports, patrimonial reports, negative events, heirs reports, worldwide KYC (PEP, sanction lists, adverse media). Use for due diligence, creditworthiness, AML/KYC questions.

日本語の概要は準備中です。原文の説明を表示しています。

Advanced CV for infrastructure inspection including forest fire detection, wildfire precondition assessment, roof inspection, hail damage analysis, thermal imaging, and 3D Gaussian Splatting reconstruction. Expert in multi-modal detection, insurance risk modeling, and reinsurance data pipelines. Activate on "fire detection", "wildfire risk", "roof inspection", "hail damage", "thermal analysis", "Gaussian Splatting", "3DGS", "insurance inspection", "defensible space", "property assessment", "catastrophe modeling", "NDVI", "fuel load". NOT for general drone flight control, SLAM, path planning, or sensor fusion (use drone-cv-expert), GPU shader development (use metal-shader-expert), or generic object detection without inspection context (use clip-aware-embeddings).

日本語の概要は準備中です。原文の説明を表示しています。

Plan database migrations before executing them: risk assessment, dependency mapping, multi-service sequencing, rollback budgets, and stakeholder communication plans. Use when deciding HOW to migrate, not when writing the actual DDL. NOT for: writing migration SQL (use database-migration-manager), data ETL pipelines (use data-migration-specialist), query optimization, or ORM configuration.

日本語の概要は準備中です。原文の説明を表示しています。

Queries PharmGKB / CPIC / DPWG for drug-gene interactions; calls CYP2D6/CYP2C9/CYP2C19/DPYD/TPMT/NUDT15/UGT1A1/SLCO1B1 star alleles and phenotype with PharmCAT, Cyrius (CYP2D6 structural variants), Aldy, Stargazer; applies Caudle 2020 activity-score translation. Use when implementing pharmacogenomic-guided prescribing, applying CPIC vs DPWG guidance, screening HLA risk alleles for ICI / antiepileptics / abacavir, or interpreting compound TPMT+NUDT15 thiopurine risk.

日本語の概要は準備中です。原文の説明を表示しています。

Infers genetic super-population ancestry from a 23andMe/AncestryDNA file and computes ancestry-stratified odds ratios with an exploratory Ancestry Elevation Score (AES) showing where ancestry-specific GWAS effect sizes diverge from European reference estimates.

日本語の概要は準備中です。原文の説明を表示しています。

Determines whether bone mineral density (BMD) measurement is indicated when patients have osteoporosis risk factors or have discontinued sex hormone therapy following gonadectomy. Clinical triggers include documented osteoporosis risk factors (e.g., low body weight, glucocorticoid use, prior fracture) or cessation of sex hormone therapy after surgical gonadectomy.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends early delivery based on individualized risk assessment rather than expectant management for pregnant patients with preexisting diabetes mellitus (PDM). Consider when evaluating delivery timing in the presence of diabetes‑related complications, suboptimal glycemia, abnormal fetal growth, or maternal comorbidities that may increase perinatal risk beyond 38 weeks gestation.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends real-time CGM with confirmatory bedside POC-BG monitoring for insulin dosing adjustments rather than POC-BG testing alone in adults with insulin-treated diabetes at high risk of hypoglycemia. Consider this approach for patients aged ≥65 years, BMI ≤27 kg/m², total daily insulin dose ≥0.6 units/kg, CKD stage ≥3, or recent hypoglycemia.

日本語の概要は準備中です。原文の説明を表示しています。

Suggests initiating inpatient continuous glucose monitoring (CGM) for select hospitalized patients at high risk for hypoglycemia, combined with periodic point-of-care glucose checks for accuracy. Triggers include planning glucose monitoring for inpatients with prior severe hypoglycemia, renal or hepatic dysfunction, or age 65 years or older.

日本語の概要は準備中です。原文の説明を表示しています。

This skill recommends discussing and offering age-appropriate vaccinations (influenza, herpes zoster, pneumococcal) to patients with Cushing’s syndrome due to increased infection risk. Use when reviewing preventive care for a CS patient; triggers include discussing preventive care, vaccination status, or infection risk in a CS patient.

日本語の概要は準備中です。原文の説明を表示しています。

Suggests considering mineralocorticoid receptor antagonists when benefits outweigh risks in pregnant or preconception PA patients with uncontrolled hypertension and hypokalemia. Triggered when standard therapy fails and clinicians ask 'Should I consider MRAs despite pregnancy?' or when assessing risk‑benefit of MRA use.

日本語の概要は準備中です。原文の説明を表示しています。

Decide when to order coronary artery calcium (CAC) scoring in a primary-prevention patient and interpret the result per the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers the Class 1 indication (men ≥40 / women ≥45, borderline / intermediate PREVENT-ASCVD risk, uncertainty about LLT), CAC score interpretation (0, 1–99, 100–299, ≥300, ≥1000), how CAC modifies LDL and non-HDL goals, when to repeat CAC, and pitfalls (incidental CAC on non-cardiac CT, radiation, cost). Use when a clinician asks should I order a CAC score, CAC indications, what does CAC 150 mean, treatment goals with CAC score, repeat CAC frequency, CAC in a smoker, CAC vs CCTA, is CAC useful in intermediate risk. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.

日本語の概要は準備中です。原文の説明を表示しています。

Set absolute LDL-C, non-HDL-C, and ApoB treatment goals, PLUS percent LDL-C reduction, for a primary-prevention patient on lipid-lowering therapy per the re-introduced treatment goals in the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers goals by PREVENT-ASCVD category (low / borderline / intermediate / high), by CAC score, in severe hypercholesterolaemia / FH, in diabetes with multiple ASCVD risk factors, and the ApoB targets once LDL-C and non-HDL-C goals are met. Use when a clinician asks what LDL goal to aim for, LDL target for intermediate risk, non-HDL goal, ApoB target, dual goals on statin, patient at goal or not, how low should LDL go, statin not enough what next. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.

日本語の概要は準備中です。原文の説明を表示しています。

Order and interpret lipoprotein(a) [Lp(a)] measurement at least once in a lifetime, apply the risk-enhancer threshold (≥125 nmol/L or ≥50 mg/dL), and run cascade screening of first-degree relatives for premature ASCVD, familial hypercholesterolaemia, or elevated Lp(a) per the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers the Class 1 lifetime measurement, how elevated Lp(a) affects LLT initiation and intensification, the cascade screening indications, the interaction of Lp(a) with ASCVD risk estimation, and current therapeutic limitations. Use when a clinician asks when to check Lp(a), how often to repeat Lp(a), elevated Lp(a) what next, treatment for high Lp(a), should I screen my patient's family, Lp(a) and statins, cascade screening indications. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.

日本語の概要は準備中です。原文の説明を表示しています。

Deep-dive framework for analyzing crypto tokens — market data, liquidity health, tokenomics, unlock schedules, and risk assessment. Combines on-chain data, API queries, and multi-source validation to generate actionable investment verdicts.

日本語の概要は準備中です。原文の説明を表示しています。

Automate 21risk tasks via Rube MCP (Composio). Always search tools first for current schemas.

日本語の概要は準備中です。原文の説明を表示しています。

Prepare and risk-check the next rolling-wave slice for implementation. Use when the user wants to continue a rolling-wave project, draft one bounded slice in the main context by default, use a fresh planning author only when context or discovery cost warrants it, use a fresh preparation reviewer when semantic risk or uncertainty warrants independent pressure-testing, decompose parallel implementation chunks where appropriate, identify agent, human, either, or hybrid execution fit, write or update docs/rolling-wave/{project}/slices/NNN-slug.md, and mark that slice ready even when other slices are active.

日本語の概要は準備中です。原文の説明を表示しています。